Drug Groups

approved

Description

A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. [PubChem]

Indication

For the treatment of mild to moderate asthma

Pharmacology

Nedocromil is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness.

Toxicity

Side effects include headache, nasal congestion, ocular burning, irritation and stinging, unpleasant taste, cough, difficulty breathing, noisy breathing, shortness of breath, tightness in chest, wheezing, conjunctivitis, blurred vision, change in color vision, difficulty seeing at night, increased sensitivity of eyes to sunlight.

Affected Organisms

Biotransformation

Nedocromil is not metabolized after IV administration and is excreted unchanged.

Absorption

Low

Half Life

~3.3 hours

Protein Binding

approximately 89% protein bound in human plasma over a concentration range of 0.5 to 50 µg/mL

Elimination

It is not metabolized and is eliminated primarily unchanged in urine (70%) and feces (30%).

External Links